glp-1 agonist adverse effects Clinical Recommendations to Manage Gastrointestinal Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1: Genetic Variants Related to

Description

However, we cannot completely rule out residual confounding

Millimans research helps assess the impact of GLP-1sfrom potential market size for pharmaceutical manufacturers to reimbursement trends and utilization management strategies for payersto help stakeholders across the healthcare ecosystem adapt

Medication availability became a more prominent issue during specific time periods

Moreover, offering oral GLP1 options allows primary care providers to meet patient preferences without compromising efficacy

The global obesity GLP-1 market size accounted for USD 8.21 billion in 2025 and is predicted to increase from USD 10.12 billion in 2026 to approximately USD 66.57 billion by 2035, expanding at a CAGR of 23.28% from 2026 to 2035